Keith Regnante is CFO at Keros Therapeutics, Inc. (KROS). They have made 4 open-market trades across 2 companies since 2018, most recently 2026-02-18.
CIK 0001682068
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| KROS | 39,261 | $419K |
| WVE | 29,186 | $91K |
| Total | $511K |
Shares reported on the most recent Form 4, priced at the 2026-02-20 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KROS | SELL | 2026-02-18 | 2026-02-20 | $16.35 | $77K | -14.1% | -29.9% | -30.0% |
| KROS | SELL | 2024-01-04 | 2025-01-24 | $45.29 | $1.8M | -5.7% | -8.6% | +22.2% |
| KROS | SELL | 2023-11-04 | 2024-01-08 | $45.29 | $1.8M | +3.6% | +0.6% | +23.7% |
| KROS | SELL · 10b5-1 | 2023-06-08 | 2023-06-12 | $46.61 | $3.7M | +0.9% | -2.4% | -11.2% |
| WVE | SELL · 10b5-1 | 2019-02-19 | 2019-02-21 | $36.84 | $48K | +22.1% | +8.8% | -32.4% |
| WVE | SELL | 2018-09-24 | 2018-09-26 | $55.00 | $1.6M | -19.7% | -17.1% | -21.1% |
| WVE | SELL · 10b5-1 | 2018-02-16 | 2018-02-21 | $51.85 | $16K | -3.4% | -21.8% | -16.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.